SCHEMBL13229397

SCHEMBL13229397

Cc1ccc(-c2ccc3c(c2)N(Cc2c[nH]cn2)CC3)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 8/20 0.40
SLC22A12 Q96S37 1/20 0.36
TRPM5 Q9NZQ8 1/20 0.34
HDAC1 Q13547 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
NOTUM Q6P988 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
BRD4 O60885 1/20 0.33
SCD O00767 1/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 2/20 0.32
POLB P06746 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
NFKB1 P19838 1/20 0.32
HIF1A Q16665 1/20 0.32
REN P00797 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526848 0.90 HDAC1 (0.40) CDK9SLC22A12TRPM5HDAC1HDAC6
SCHEMBL13229395 0.90 SLC22A12 (0.39) CDK9SLC22A12TRPM5HDAC1HDAC6
SCHEMBL13229407 0.89 HDAC1 (0.43) CDK9SLC22A12TRPM5HDAC1HDAC6
SCHEMBL13229357 0.89 HDAC1 (0.43) CDK9SLC22A12TRPM5HDAC1HDAC6
SCHEMBL13229383 0.88 CDK9 (0.40) CDK9SLC22A12TRPM5NOTUMTAAR1
SCHEMBL13229483 0.88 HRH3 (0.39) CDK9HDAC1HDAC6BRD4SCD
SCHEMBL13229365 0.88 HRH3 (0.41) CDK9SLC22A12TRPM5HDAC1HDAC6
SCHEMBL13229480 0.88 TRPV1 (0.41) CDK9TRPM5HDAC1HDAC6TAAR1
SCHEMBL13229405 0.87 HDAC1 (0.41) CDK9SLC22A12TRPM5HDAC1HDAC6
SCHEMBL13229072 0.86 REN (0.36) CDK9SLC22A12TRPM5NOTUMTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501747-B2 Functionally selective alpha2C adrenoreceptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
US-8501747-B2 Functionally selective alpha2C adrenoreceptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) 2010-08-05 US disclosed
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) 2010-08-05 US disclosed
WO-2008100456-A2 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS ADRA2C, ADRB2, ADRB3 CDK9 4510/4885SLC22A12 2838/4885TRPM5 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.